No history of other malignancy within the past  years, except for malignancies with a > % likelihood of cure (e.g. non-melanoma skin cancer, papillary thyroid cancer, in situ cervical cancer); patients cannot have metastatic breast or other cancer
No concurrent malignancy other than non-melanoma skin cancer, superficial noninvasive (pTa or pT in situ [is]) transitional cell carcinoma (TCC) of the bladder, contralateral GCT, or intratubular germ cell neoplasia; patients with a prior malignancy, but at least  years since any evidence of disease are allowed
History of prior or current synchronous malignancy, except:\r\n* Malignancy that was treated with curative intent and for which there has been no known active disease for >  years prior to enrollment\r\n* Curatively treated non-melanoma skin cancer, cervical cancer in situ, or prostatic intraepithelial neoplasia, without evidence of prostate cancer
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: The subject has had another active malignancy within the past three years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin; questions regarding the inclusion of individual subjects should be directed to the study chair
EXCLUSION CRITERIA FOR THIRD -LINE THERAPY: The subject has had another active malignancy within the past three years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin; questions regarding the inclusion of individual subjects should be directed to the study chair
Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy
No history of prior or synchronous malignancy, except\r\n* Prior malignancy was treated with curative intent and there is no known active disease present for greater than or equal to  years prior to study entry\r\n* Participants with adequately treated non-melanoma skin cancers, cervical carcinoma in situ, or prostatic intraepithelial neoplasia without evidence of prostate cancer are eligible
Patients with an active second malignancy (other than non-melanoma skin cancer or cervical cancer in situ) are NOT eligible for participation
History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least  years;\r\n* Exceptions: non-melanoma skin cancer and in situ cervical cancer
Must not have an active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ; patients with history of malignancy are eligible provided primary treatment of that cancer was completed >  year prior to registration and the patient is free of clinical or radiologic evidence of recurrent or progressive malignancy
Active malignancy (other than NSCLC, non melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, LCIS/DCIS of the breast, or localized prostate cancer) within the last  years prior to randomization.
Any other malignancy requiring anti-tumor treatment in the past three years, excluding treated stage I prostate cancer, in situ cervical cancer, in situ breast cancer and non-melanomatous skin cancer
Participant has a history of invasive cancer (other than non-melanoma skin cancer or cervical cancer in situ) active within  months prior to the baseline study visit; (participants who have a history of cancer that was curatively treated without evidence of recurrence in the  months prior to the baseline study visit are considered eligible)
Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer
Will need or has needed active treatment of a second malignancy within the prior  years before enrollment, other than FL, non-melanoma skin cancers, localized prostate cancer treated with curative intent, or cervical carcinoma in situ
The patient has an additional active malignancy that may confound the assessment of the study endpoints. Patients with a past cancer history (active malignancy within  years prior to study entry) with substantial potential for recurrence must be discussed with the Sponsor before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia), organ-confined prostate cancer with no evidence of progressive disease.
DONOR: Related donors: no history of opportunistic infections, autoimmunity, hemoglobinopathy, red cell enzymopathy, or malignancy, apart from non-melanomatous skin cancer or healed cervical cancer in situ
Other malignancy within  years prior to entry into the study, except for treated early-stage melanoma or non-melanoma skin cancer, cervical carcinoma in situ, incidental or localized prostate cancer treated with prostatectomy or radiation therapy, or stage I colon cancer. Patients with other completely resected malignancies in the prior three years and no evidence of disease will be evaluated on a case-by-case basis with eligibility determined based on discussion with the principal investigator
Concurrent active malignancy or prior malignancy that was active within the previous  years (other than completely resected carcinoma in situ, prostate cancer, or localized non-melanoma skin cancer)
History of any malignancy within the last  months except for those specified in this protocol and low-grade malignancies not requiring active treatment such as non-melanoma skin cancer, cervical intraepithelial neoplasia, or prostate cancer in situ.
History of other carcinomas within the last five years, except cured non-melanoma skin cancer, curatively treated in-situ cervical cancer, or localized prostate cancer with a current PSA of < . mg/dL on  successive evaluations, at least  months apart, with the most recent evaluation no more than  weeks prior to the start of study drug
Any evidence of metastatic disease or another active malignancy within the past two years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.
Any malignancy that required treatment (except non-melanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ), within  years prior to study drug administration.
Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, localized/stable renal masses, ductal carcinoma in situ (DCIS)/lobular carcinoma in situ (LCIS) of the breast, or localized and presumed cured prostate cancer) within the last  years
Other prior or concomitant malignancies with the exception of:\r\n* Non-melanoma skin cancer\r\n* In-situ malignancy\r\n* Low-risk prostate cancer after curative therapy\r\n* Other cancer for which the patient has been disease free for >=  years before the first dose of study drug and of low potential risk for recurrence
No active second cancers with the exception of localized non-melanoma skin cancer, in-situ cervical or in-situ bladder cancer
Any other malignancy which has been active or treated within the past three years, with the exception of cervical intra-epithelial neoplasia and non-melanoma skin cancer
Patients with active malignancy (not including basal cell carcinoma, non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer treated with hormone therapy). Patients with history of other cancers should be free of disease for at least  years.
No active malignancy except for nonmelanoma skin cancer or in situ cervical cancer or treated non-pelvic cancer from which the patient has been continuously disease free more than three years
Prior malignancy within  years of enrollment excluding non?melanoma skin cancer or cervical carcinoma after curative resection, not requiring chemotherapy
Prior history of another malignancy (except for non-melanoma skin cancer, in situ cervical or breast cancer, or localized prostate cancer) unless disease free for at least one year and felt at low risk of relapse by treating physician
Concurrent (or within the last  years) second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, controlled superficial bladder cancer, or other carcinoma in situ that has been treated
Other malignancy: patients will not be eligible if they have evidence of active malignancy (other than non-melanoma skin cancer or localized cervical cancer, or localized and presumed cured prostate cancer).
History of prior malignancy with the exception of cervical intraepithelial neoplasia, non-melanoma skin cancer, and adequately treated localized prostate carcinoma (PSA <.). Patients with a history of other malignancies must have undergone potentially curative therapy and have no evidence of that disease for five years
Other active malignancy except for localized skin cancer, bladder, prostate, breast or cervical carcinoma in situ
History of another malignancy within  years prior to study entry, except curatively treated non-melanotic skin cancer, cervical cancer in situ, localized biopsy-proven prostate cancer, or stage I colon cancer
Other active malignancy: EXCEPTIONS: Non-melanoma skin cancer, localized prostate cancer, or carcinoma-in-situ of the cervix; NOTE: If there is a history or prior malignancy, patient must not be receiving other cytotoxic or molecularly targeted therapeutics treatment for their cancer; patients receiving certain hormonal manipulations as part of their treatment may be allowed to continue at the discretion of the Principal Investigator (PI) (e.g. luteinizing hormone-releasing hormone [LHRH] analogs for prostate cancer)
Any other malignancy that required treatment (except for non-melanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ), within  years prior to study drug administration
History of active malignancy in past  years (non-melanoma skin cancer or cervical cancer in situ permitted)
History of other cancer within  years (except non-melanoma cutaneous malignancies and cervical carcinoma in situ).
The subject has had another active malignancy within the past five years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin; questions regarding the inclusion of individual subjects should be directed to the principle investigator
Treatment for other carcinomas within the last  years, except non-melanoma skin cancer and treated cervical carcinoma in-situ (CCIS)
Another malignancy undergoing active treatment with the exception of non-melanoma skin cancer or in situ cervical cancer
Subjects with active malignancy and/or cancer history that may confound the assessment of the study endpoints; patients with a past cancer history (within  years of entry) with substantial potential for recurrence and/or ongoing active malignancy must be discussed with the principal investigator (PI) before study entry; this exclusion criterion does not apply to: non-melanoma skin cancer, carcinoma in situ (including superficial bladder cancer), cervical intraepithelial neoplasia, and organ-confined prostate cancer with no evidence of progressive disease
History of a second malignancy within the previous  years (except non-melanoma skin cancer and cervical in-situ)
Carcinoma in situ or non-melanoma skin cancer
Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy.
History of other cancer within  years (except non-melanoma cutaneous malignancies and cervical carcinoma in situ).
Subject has no other malignancy within  years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in-situ cervical cancer or incidental histological finding of prostate cancer (TNM stage of Ta or Tb); all treatments of which should have been completed  months prior to signing ICF.
The patient has an active malignancy and/or cancer history (excluding AML, BPDCN, or antecedent MDS) that may confound the assessment of the study endpoints. Patients with a past cancer history (within  years of entry) with substantial potential for recurrence and/or ongoing active malignancy must be discussed with the Sponsor before study entry. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, cervical intraepithelial neoplasia, organ-confined prostate cancer with no evidence of progressive disease.
Other clinically significant malignant disease diagnosed within the previous  years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer.
History of other cancer within  years (except non-melanoma cutaneous malignancies and cervical carcinoma in situ). For patients enrolled in Part  of the Site-specific Amendment, history of other cancer within  year (except non-melanoma cutaneous malignancies and cervical carcinoma in situ. Concurrent active cancers are not allowed).
History of other cancer within  years (except non-melanoma cutaneous malignancies and cervical carcinoma in situ)
Active second primary malignancy other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy determined not be exclusionary.
Prior malignancy except for prior BRCA-associated cancer as long as there is no current evidence of the prior cancer, carcinoma in situ of the cervix or non-melanoma skin cancer, and a cancer diagnosed and definitively treated > years prior to study enrollment with no subsequent evidence of recurrence
Additional active malignancy that may confound the assessment of the study endpoints. Patients with a past cancer history with substantial potential for recurrence must be discussed with the Medical Monitor before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia, and melanoma in situ), organ-confined prostate cancer with no evidence of progressive disease.
Concurrent malignancy or prior malignancy within the previous  years (other than completely resected carcinoma in situ, prostate cancer, or localized non-melanoma skin cancer)
History of other invasive malignancy, with the exception of non-melanoma skin cancer and well-excised cervical carcinoma in situ, =<  years prior to enrollment unless assessed by the principal investigator as unlikely to compromise subject safety or to interfere with the study's objectives
Concurrent malignancy (other than adequately treated non-melanoma skin cancer, superficial transitional cell carcinoma of the bladder, and cervical carcinoma in situ) diagnosed within the past  years or any currently active malignancy
Patients with a history of another active malignancy within the past two years, with the exception of non-melanoma cutaneous malignancy, cervical carcinoma in situ, or ductal carcinoma in situ which has been successfully treated with curative intent therapy
Other coexisting malignancies or malignancies diagnosed within the previous  years no evidence of disease for at least  years; exceptions to this include non-melanoma skin cancer, cervical cancer in situ, well differentiated thyroid cancer or prostate cancer; other cancers that per assessment of the PI are not prognosis limiting can be allowed after review by the PI
Patients currently being actively treated or who have been treated within the past  years for an unrelated malignancy (except non-melanoma skin cancer, cervical carcinoma in-situ, and low risk prostate cancer)
Subjects being actively treated for a secondary malignancy or any malignancy within the last  years, with the exception of non-melanomatous skin cancer or localized, definitively treated cervical cancer. Men under observation for local prostate cancer are also eligible if they have had stable disease for at least  year.
Prior malignancy except for non-melanoma skin cancer and carcinoma in situ, unless diagnosed and definitively treated more than  years prior to enrollment
Diagnosed with a malignancy in the past two years. However, subjects with non-melanoma skin cancers, melanoma in situ, localized cancer of the prostate with current PSA of <. ng/mL, treated thyroid cancer or cervical carcinoma in situ or ductal/lobular carcinoma in situ of the breast within the past two years may enroll as long as there is no current evidence of disease.
Other prior or concomitant malignancies with the exception of:\r\n* Non-melanoma skin cancer\r\n* In-situ malignancy\r\n* Low-risk prostate cancer after curative therapy\r\n* Other cancer for which the patient has been disease free for >=  years
History of another malignancy not in remission for at least  yrs (except non-melanoma skin cancer, stage  melanoma, localized prostate cancer, cervical cancer in situ)
Other active malignancies with the exception of:\r\n* Non-melanoma skin cancer\r\n* Cervical carcinoma in situ without evidence of disease\r\n* Prostatic intraepithelial neoplasia without evidence of prostate cancer
History of prior or synchronous malignancy except:\r\n* A malignancy that was treated with curative intent and for which there has been no known active disease for >  years prior to randomization\r\n* Curatively treated non-melanoma skin malignancy, cervical cancer in situ, or prostatic intraepithelial neoplasia without evidence of prostate cancer
Patients with an active second malignancy (other than non-melanoma skin cancer or cervical cancer in situ) are NOT eligible for participation
Women who have completed treatment for other malignancies (except non-melanomatous skin cancer) <  years from their new diagnosis of cervical cancer
Treatment for other carcinomas within the last two years, except cured non-melanoma skin, low-risk prostate cancer, non-invasive bladder cancer, or treated in-situ cervical cancer
Concurrent malignancy except for treated non-melanoma skin cancer, cervical carcinoma in situ and low-risk prostate cancer antigen (CA) being monitored without treatment
A diagnosis of another active malignancy with the exception of non-melanoma skin cancer or cervical cancer in situ
History of an active malignancy or prior malignancy except for the following: patients greater than  years out from their diagnosis and or treatment, patients with local malignancies who have undergone localized therapy felt to be curative (e.g., colposcopy resection of in situ cervical carcinoma, surgically resected non-melanoma skin cancer, local irradiation, surgery, or ablative radioactive iodine treatment for local thyroid cancer); patients who have undergone such interventions should be greater than one year from therapy without evidence of recurrence
Subject has another past or active malignancy which requires treatment. Prior carcinoma in situ or non-melanoma skin cancer after curative resection are permitted.
The subject has had another active malignancy within the past three years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin; questions regarding the inclusion of individual subjects should be directed to the principal investigator
Subject has another past or active malignancy that requires treatment. Prior carcinoma in situ and/or nonmelanoma skin cancer after curative resection are permitted.
Other malignancy within  years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.
Malignancies within the past  years other than non-melanoma skin cancer or in situ cervical cancer status post treatment
Other active malignancy except for non melanoma skin cancer or in situ cervical or breast cancer.
Patient has had an active solid tumor malignancy within the last  years from screening, except for cervical carcinoma in situ localized prostate cancer or nonmelanoma skin cancer that has been definitively treated.
The subject has had another active malignancy within the past five years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin; questions regarding the inclusion of individual subjects should be directed to the Principal Investigator
No active concurrent malignancy with the exception of superficial non-melanoma skin cancer and cervical carcinoma in situ
Concurrent malignancy except for treated non-melanoma skin cancer and cervical carcinoma in situ
The patient has an active malignancy and/or cancer history (excluding AML or antecedent myelodysplastic syndrome [MDS]) that may confound the assessment of the study endpoints. Patients with a past cancer history (within  years of entry) with substantial potential for recurrence and/or ongoing active malignancy must be discussed with the Sponsor before study entry. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including superficial transitional cell carcinoma of the bladder), cervical intraepithelial neoplasia, organ-confined prostate cancer with no evidence of progressive disease.
History of previous malignancy excluding non-melanoma skin lesions and in-situ cervical cancer; patients with other malignancies are eligible if they have been disease free for >=  years
Have a secondary malignancy within the last  years prior to first dose of study drug, excluding treated non-melanoma skin cancer, carcinoma in situ, or locally-treated prostate cancer
Concurrent (within the last  years) second malignancy other than non melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer
Any malignancy that required treatment, or has shown evidence of recurrence (except for soft tissue sarcoma, non-melanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ) during the  years prior to randomization.
Any malignancy within past -years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer
Any malignancy within past -years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer
Prior or nd malignancy, except non-melanoma skin cancer, completely resected cervical or prostate cancer (with PSA of less than or equal to . ng/ml), or other cancer for which the subject has received curative therapy at least  yrs prior to study entry
Prior or nd malignancy, except non-melanoma skin cancer, completely resected cervical or prostate cancer (with PSA of less than or equal to . ng/ml), or other cancer for which the subject has received curative therapy at least  yrs prior to study entry
Active malignancy, other than NHL, within the past  years except for localized prostate cancer treated with hormone therapy, cervical carcinoma in situ, breast cancer in situ, or non-melanoma skin cancer following definitive treatment
Concurrent diagnosis of other active malignancies with the exception of ductal carcinoma in situ, cervical carcinoma in situ, and localized non-melanoma skin cancer
Active second malignancy in the last  years except for non-melanoma skin cancer or carcinoma-in-situ
Patients with a history of another active malignancy within the past two years, with the exception of non-melanoma cutaneous malignancy, cervical carcinoma in situ, or ductal carcinoma in situ which has been successfully treated with curative intent therapy
Research participants with presence of other active malignancy within  years of study entry; participants with history of prior malignancy treated with curative intent who achieved complete remission (CR) more than  years before study entry are eligible; this exclusion rule does not apply to non-melanoma skin tumors and in-situ cervical cancer
Active malignancy within  years of entry, except previously treated non-melanoma skin cancer, carcinoma in situ or cervical intraepithelial neoplasia, and organ confined prostate cancer with no evidence of progressive disease based on PSA levels and are not on active therapy.
Participants with a history of a different malignancy are ineligible unless they have been disease free for  year and considered at low risk for relapse, except for: cervical cancer in situ, ductal carcinoma in situ, localized prostate cancer with no detectable disease by imaging studies, and non-melanoma cancers of the skin, which are eligible at any time
Concurrent other active malignancy (other than non-melanoma skin cancer or in situ cervical cancer)
Has a history of other malignant tumors within the last  years, except non melanoma skin cancer or in situ cervical carcinoma curatively excised
Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
History of malignant tumors other than SCCHN within the last  years, except non-melanoma skin cancer or curatively excised in situ cervical carcinoma
Patients with concurrent invasive malignancy other than non-melanoma skin cancer or cervical intraepithelial neoplasia unless the treating physician considers it unlikely to impact the clinical outcome of the patient
Participants must not have a current or prior invasive malignancy within the past  months; participants may enroll prior to biopsy result report, unless there are findings at bronchoscopy suggesting an invasive malignancy; history of the following curatively treated cancers during any time prior to screening is allowed: non-melanoma skin cancer, cervical carcinoma in situ, and bladder carcinoma in situ
Patients with a history of any other malignancy within  years except non-melanoma skin and cervical carcinoma in situ (CIS)
Prior malignancy that required treatment, or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the  years prior to randomization.
Any other malignancy known to be active or treated within  years of start of screening, except cervical intra-epithelial neoplasia and non-melanoma skin cancer
An active malignancy and/or cancer history for at least  years with the exception of non-melanoma skin cancer, carcinoma in situ, cervical intraepithelial neoplasia, organ-confined prostate cancer with no evidence of progressive disease.
Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy determined not be exclusionary.
Any prior history of invasive malignancy within the past  years except non-melanoma skin cancer, carcinoma in-situ, localized prostate cancer without biochemical recurrence following definitive treatment
